Therapeutics News and Research

RSS

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers.

3 Mar 2015

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.

2 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

2 Mar 2015

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Transition Therapeutics Inc. announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD").

2 Mar 2015

New book provides in-depth, advanced understanding of Ebola and rabies viruses

Significant human and animal pathogens remain major scourges to human health. Recent devastating Ebola virus disease outbreak in West Africa underscores the importance of understanding the biology of replication and response of host cells to infection by these pathogens.

28 Feb 2015

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs.

28 Feb 2015

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation.

28 Feb 2015

Two cancer centres partner to advance personalized therapies against cancer

Two internationally acclaimed cancer centres today announced a partnership to accelerate academic and clinical research to advance personalized, targeted therapies against cancer.

28 Feb 2015

Targeting stroma could potentially extend survival of pancreatic cancer patients

Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma.

27 Feb 2015

Lyric announces initial closing of $20.4 million Series A financing round

Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Sante Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.

26 Feb 2015

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.

26 Feb 2015

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months.

25 Feb 2015

Researchers find that new targeted drugs can attack weak spots in cancer cells

Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs.

25 Feb 2015

Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics shows that only about 1 percent of triple-negative breast cancer cells in a tumor must be "androgen-receptor-positive" to show benefit from anti-androgen therapies.

25 Feb 2015

N30 Pharmaceuticals becomes Nivalis Therapeutics

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).

24 Feb 2015

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical.

24 Feb 2015

Study identifies small loop in human prion protein that resists chronic wasting disease

Chronic wasting disease (CWD) — an infectious disease caused by prions — affects North American elk and deer, but has not been observed in humans. Using a mouse model that expresses an altered form of the normal human prion protein, researchers at University of California, San Diego School of Medicine have determined why the human proteins aren't corrupted when exposed to the elk prions.

24 Feb 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix™, a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).

23 Feb 2015

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention.

21 Feb 2015

Therapeutics News and Research

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

New book provides in-depth, advanced understanding of Ebola and rabies viruses

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Two cancer centres partner to advance personalized therapies against cancer

Targeting stroma could potentially extend survival of pancreatic cancer patients

Lyric announces initial closing of $20.4 million Series A financing round

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

Researchers find that new targeted drugs can attack weak spots in cancer cells

Study shows that even breast cancers with few androgen receptors benefit from anti-androgen therapy

N30 Pharmaceuticals becomes Nivalis Therapeutics

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Study identifies small loop in human prion protein that resists chronic wasting disease

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

MD Anderson awarded more than $22 million in research grants from CPRIT

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News